Sign In
Buy DGX
Quest Diagnostics Earnings Calls
| Release date | Apr 21, 2026 |
| EPS estimate | $2.37 |
| EPS actual | $2.50 |
| EPS Surprise | 5.49% |
| Revenue estimate | 2.829B |
| Revenue actual | 2.895B |
| Revenue Surprise | 2.35% |
| Release date | Feb 10, 2026 |
| EPS estimate | $2.36 |
| EPS actual | $2.42 |
| EPS Surprise | 2.54% |
| Revenue estimate | 2.754B |
| Revenue actual | 2.806B |
| Revenue Surprise | 1.88% |
| Release date | Oct 21, 2025 |
| EPS estimate | $2.50 |
| EPS actual | $2.60 |
| EPS Surprise | 4.00% |
| Revenue estimate | 2.736B |
| Revenue actual | 2.816B |
| Revenue Surprise | 2.94% |
| Release date | Jul 22, 2025 |
| EPS estimate | $2.57 |
| EPS actual | $2.62 |
| EPS Surprise | 1.95% |
| Revenue estimate | 2.725B |
| Revenue actual | 2.761B |
| Revenue Surprise | 1.32% |
Last 4 Quarters for Quest Diagnostics
Below you can see how DGX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 22, 2025 |
| Price on release | $178.24 |
| EPS estimate | $2.57 |
| EPS actual | $2.62 |
| EPS surprise | 1.95% |
| Date | Price |
|---|---|
| Jul 16, 2025 | $167.03 |
| Jul 17, 2025 | $168.18 |
| Jul 18, 2025 | $166.91 |
| Jul 21, 2025 | $166.45 |
| Jul 22, 2025 | $178.24 |
| Jul 23, 2025 | $170.48 |
| Jul 24, 2025 | $171.90 |
| Jul 25, 2025 | $168.55 |
| Jul 28, 2025 | $167.85 |
| 4 days before | 6.71% |
| 4 days after | -5.83% |
| On release day | -4.35% |
| Change in period | 0.491% |
| Release date | Oct 21, 2025 |
| Price on release | $184.64 |
| EPS estimate | $2.50 |
| EPS actual | $2.60 |
| EPS surprise | 4.00% |
| Date | Price |
|---|---|
| Oct 15, 2025 | $187.35 |
| Oct 16, 2025 | $186.82 |
| Oct 17, 2025 | $189.51 |
| Oct 20, 2025 | $190.41 |
| Oct 21, 2025 | $184.64 |
| Oct 22, 2025 | $181.17 |
| Oct 23, 2025 | $183.23 |
| Oct 24, 2025 | $182.18 |
| Oct 27, 2025 | $180.26 |
| 4 days before | -1.45% |
| 4 days after | -2.37% |
| On release day | -1.88% |
| Change in period | -3.78% |
| Release date | Feb 10, 2026 |
| Price on release | $205.35 |
| EPS estimate | $2.36 |
| EPS actual | $2.42 |
| EPS surprise | 2.54% |
| Date | Price |
|---|---|
| Feb 04, 2026 | $189.23 |
| Feb 05, 2026 | $192.30 |
| Feb 06, 2026 | $190.71 |
| Feb 09, 2026 | $191.25 |
| Feb 10, 2026 | $205.35 |
| Feb 11, 2026 | $209.32 |
| Feb 12, 2026 | $206.86 |
| Feb 13, 2026 | $206.87 |
| Feb 17, 2026 | $205.49 |
| 4 days before | 8.52% |
| 4 days after | 0.0682% |
| On release day | 1.93% |
| Change in period | 8.59% |
| Release date | Apr 21, 2026 |
| Price on release | $205.04 |
| EPS estimate | $2.37 |
| EPS actual | $2.50 |
| EPS surprise | 5.49% |
| Date | Price |
|---|---|
| Apr 15, 2026 | $191.42 |
| Apr 16, 2026 | $191.46 |
| Apr 17, 2026 | $195.02 |
| Apr 20, 2026 | $196.31 |
| Apr 21, 2026 | $205.04 |
| Apr 22, 2026 | $204.00 |
| Apr 23, 2026 | $199.53 |
| Apr 24, 2026 | $196.27 |
| Apr 27, 2026 | $196.63 |
| 4 days before | 7.12% |
| 4 days after | -4.10% |
| On release day | -0.507% |
| Change in period | 2.72% |
Quest Diagnostics Earnings Call Transcript Summary of Q1 2026
Quest Diagnostics reported a strong Q1 2026 driven almost entirely by organic growth across physician, hospital and consumer channels. Consolidated revenue was $2.9 billion, up 9.2% year-over-year, with organic revenue growth of 9% and adjusted EPS of $2.50 (up ~13% YoY). Volume (requisitions) rose 10.9% aided ~7 percentage points by new partnerships with Fresenius Medical Care and Corewell Health; excluding those relationships, organic volume was 3.8%. Management highlighted double-digit growth in advanced diagnostics including AD-Detect (Alzheimer's testing), cardiometabolic markers (Lp[a], ApoB), and consumer health products (questhealth.com and third‑party partnerships). Productivity gains from automation and AI materially supported margin expansion (examples: 40% productivity improvement for AI-assisted customer service triage; ~350,000 uses of the Quest AI Companion in Q1). Quest reiterated and quantified operational initiatives: Project Nova (~$0.25 EPS headwind for 2026, with >60% of costs in H2), Invigorate (targeting ~3% annual cost savings), and $550M planned capex for 2026. Given Q1 momentum, management raised full-year 2026 guidance to $11.78–$11.90 billion in revenue (growth 6.8–7.8%) and adjusted EPS of $10.63–$10.83. Management says they see a healthy M&A pipeline and continue to pursue Co-Lab and outreach opportunities, while monitoring regulatory items (PAMA/PAMA data collection and OIG/CRUSH initiatives) but do not see material Q1 impact from those items.
